secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001193125-23-077853
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium Q4 2022: $15.8M revenue from Ono deal, net income $2.8M; cash $71M into 2025
--------------------------------------------------------------------------------

- Revenue of $15.8M in Q4 2022 from Ono Pharmaceutical asset purchase agreement; no revenue in prior year period.
- Net income of $2.8M ($0.08 per share) in Q4 2022 vs net loss of $10.6M in Q4 2021.
- Full year 2022 net loss of $62.4M ($1.85 per share) vs $39.1M loss in 2021, including non-cash in-process R&D from Bioniz acquisition.
- Cash, cash equivalents and short-term investments total $71.0M as of Dec 31, 2022; expected to fund operations into 2025.
- Partnership with Ono for itolizumab: $26.4M upfront, up to $139M in milestones, and R&D funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/0001193125-23-077853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/d471634d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-077853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer